These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37227449)

  • 1. Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
    Pabani A; Gainor JF
    Clin Cancer Res; 2023 Oct; 29(19):3841-3849. PubMed ID: 37227449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armed antibodies for cancer treatment: a promising tool in a changing era.
    Danielli R; Patuzzo R; Ruffini PA; Maurichi A; Giovannoni L; Elia G; Neri D; Santinami M
    Cancer Immunol Immunother; 2015 Jan; 64(1):113-21. PubMed ID: 25314912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody fusions with immunomodulatory proteins for cancer therapy.
    Müller D
    Pharmacol Ther; 2015 Oct; 154():57-66. PubMed ID: 26145167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
    Murer P; Neri D
    N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.
    Bootz F; Neri D
    Drug Discov Today; 2016 Jan; 21(1):180-189. PubMed ID: 26526566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the limitations of cytokines to improve cancer therapy.
    Di Trani CA; Cirella A; Arrizabalaga L; Fernandez-Sendin M; Bella A; Aranda F; Melero I; Berraondo P
    Int Rev Cell Mol Biol; 2022; 369():107-141. PubMed ID: 35777862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.
    Boersma B; Poinot H; Pommier A
    Pharmaceutics; 2024 Jul; 16(8):. PubMed ID: 39204319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
    Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
    Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytokines: a novel class of potent armed antibodies.
    Pasche N; Neri D
    Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytokines for cancer treatment: past, present and future.
    Neri D; Sondel PM
    Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in clinical cancer immunotherapy.
    Berraondo P; Sanmamed MF; Ochoa MC; Etxeberria I; Aznar MA; Pérez-Gracia JL; Rodríguez-Ruiz ME; Ponz-Sarvise M; Castañón E; Melero I
    Br J Cancer; 2019 Jan; 120(1):6-15. PubMed ID: 30413827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.
    Peng H; He X; Wang Q
    Front Immunol; 2022; 13():1035997. PubMed ID: 36405688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine engineering for targeted cancer immunotherapy.
    Bonati L; Tang L
    Curr Opin Chem Biol; 2021 Jun; 62():43-52. PubMed ID: 33684633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.